Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coenzyme I + Sintilimab + Bevacizumab in Unresectable HCC
NCT06590844Phase 4Active, not recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Dec 2023
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of nicotinamide adenine dinucleotide in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of USTC. Started Dec 2023; status: active, not recruiting.
02
Drugs
nicotinamide adenine dinucleotide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06590844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06590844.